Former Medtronic Executive Joins Leading Endovascular Device Company Endologix as CEO

On January 7, Endologix announced that President and CEO Matt Thompson, Ph.D., intends to step down.Plan to transition to Executive Vice President and Chief Medical Officer.

Therefore,The Company Appoints Dr. John Liddicoat as New President and Chief Executive Officer, the appointment takes effect immediately.

(Updated Team Organization Information on Endologix's Official Website)

Previously,Dr. Liddicoat served as an executive at Medtronic for over 16 years.。In 2018,Appointed as Executive Vice President and President of the Americas, and became a member of the Medtronic Executive Committee.

Since 2014,Dr. LiddicoatServed as Senior Vice President and President of the Cardiac Rhythm and Heart Failure (CRHF) division. During the tenure, responsible for the overall strategic direction and daily global operations of five business units within these divisions.Involving the diagnosis, treatment, and management of patients with arrhythmia and heart failure, with an annual revenue approaching $6 billion.。

In fact, with the frequent business adjustments in the past two years,MedtronicSeveral senior executives have left. Among them, Endologix, as a company specializing in the medical device field,In the first half of 2024, two former leaders of Medtronic were successively hired to join its top management., respectively serving as the Chief Commercial Officer (CCO) and Chief Operating Officer (COO) positions.

Besides, Endologix'sVice President of EngineeringAlso held a key position at Medtronic, primarily responsible for the technical development of projects in the coronary, renal denervation, and structural heart departments.

For the addition of the new senior management,Endologix stated:"We are very pleased to welcome Dr. John Liddicoat as our new Chief Executive Officer. John’s extensive experience in the healthcare industry and proven leadership make him the ideal person to lead the company into the next chapter of growth and innovation."

Endologix is a global medical device company headquartered in California, dedicated to providing innovative therapies for the interventional treatment of vascular diseases to improve patients' lives.Product portfolio covers from abdominal aortic aneurysms to peripheral vascular diseases in the lower limbs.Different Treatment Stages。

In 2020, the renowned global medical device investment firm Deerfield Partners became the company's largest controlling shareholder after the company had fallen into difficulties due to the impact of the pandemic and pressures on performance and revenue.In 2021,Endologix AnnouncesAcquisitionPQ Bypass, Obtained FDARecognitionBreakthrough DeviceDetour, including its R&D and production technology，Consolidated its leadership position in the field of abdominal aortic aneurysm treatment,And promote disruptive technologies for treating vascular diseases。

Detour System for the Treatment of Peripheral Artery Disease (PAD)，YesThe world's first fully percutaneous arterial bypass therapy,Received FDA approval via the PMA pathway in 2023, currently only sold in the United States.

The company currently has two products in the commercialization stage.Mainly for AAA (Abdominal Aortic Aneurysm) EVAR (Endovascular Aneurysm Repair). Market share in the United States10%, with approximately 100 million US dollars in revenue in 2023, and an annual growth rate of about 5%.

Among them,ALTOAdopting adaptive sealing technology, the smallest size (delivery system with an inner diameter of 13F) and the shortest neck length (7 millimeters) among EVAR implants currently on the market.AFX2Adopting a bifurcated one-piece design, it retains the native bifurcation and separates the graft fixation from the sealing zone.

Not long ago, Endologix announced the three-year clinical data of DETOUR (DETOUR 2). The data showed that the clinical outcomes of DETOUR were comparable to peripheral artery bypass surgery, while complications and deep vein thrombosisIncidence of Formation (DVT)Relatively Low, with good safety performance.

The DETOUR System consists of a dual-cage stent, a spring-like guidewire support and delivery system, and a covered self-expanding stent. It achieves blood flow transfer from the femoral-popliteal artery to the superficial femoral artery through overlapping annular stents.The entire process is guided by X-ray fluoroscopy., without the need for general anesthesia, is less invasive, and can significantly impact the treatment model for long-segment SFA disease.

This article is a reprint and share, all opinions belong to the original author.Platform, Medical DeviceMedical Business ReviewDisclaimer: All viewpoints in the article are presented neutrally, intended solely for sharing and exchange purposes.